title: A Chinese herbal Formula, Chang-Wei-Qin, Synergistically Enhances Antitumor Effect of Oxaliplatin.
abstract: Chang-Wei-Qing (CWQ), a Chinese herbal formula, has long been employed clinically to treat cancers. In this study, we investigated the synergistic effect of CWQ with oxaliplatin (OXA) on the tumor growth inhibition of orthotopic transplanted colon cancer and explored the underlying mechanism. By generating the orthotopic transplanted nude mouse model of human colon carcinoma, we found that (1) CWQ enhanced OXA-mediated tumor suppression by 4.25-fold. (2) The body weights of nude mice in CWQ group and combination group were increased. (3) The survival time of tumor-bearing nude mice was dramatically improved in CWQ and CWQ/OXA group. (4) CWQ could restore OXA-mediated deregulation of copper transporter genes, hCTR1, ATP7A and ATP7B. (5) OXA-induced drug resistance index for OXA, 5-FU, HCPT and THP were 7.59, 4.28, 5.78 and 4.50 respectively, while the reversal index by combined CWQ treatment were 6.57, 2.61, 4.97 and 3.10, respectively. Our study demonstrates that the repeated intraperitoneal injection of OXA can induce multi-drug resistance of orthotopic transplanted nude mouse model of human colon carcinoma. The CWQ treatment can alleviate OXA-triggered side effects and reverse platinum drug resistance via up-regulation of hCTR1 expression and down-regulation of ATP7A and ATP7B levels.
authors.affiliation: Department of Medical Oncology, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
authors.forename: Yong
authors.initials: Y
authors.lastname: Zhang
authors.forename: Qiang
authors.initials: Q
authors.lastname: Zhang
authors.forename: Zhongze
authors.initials: Z
authors.lastname: Fan
authors.forename: Jue
authors.initials: J
authors.lastname: Sun
authors.forename: Xulin
authors.initials: X
authors.lastname: Liu
authors.forename: Lingling
authors.initials: L
authors.lastname: Cheng
authors.forename: Ao
authors.initials: A
authors.lastname: Li
authors.forename: Jianhua
authors.initials: J
authors.lastname: Xu
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D004195:Disease Models, Animal; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D004365:Drugs, Chinese Herbal / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D009944:Organoplatinum Compounds / Q000494:pharmacology / Q000627:therapeutic use*; D000077150:Oxaliplatin; D015996:Survival Rate; D016896:Treatment Outcome; D023041:Xenograft Model Antitumor Assays
chemical_list: D000970:Antineoplastic Agents; D004365:Drugs, Chinese Herbal; D009944:Organoplatinum Compounds; C568087:changweiqing; D000077150:Oxaliplatin
references.citation: Oncol Lett. 2010 Sep;1(5):837-840
references.pmid: 22966390
references.citation: Mol Pharmacol. 2003 Aug;64(2):466-73
references.pmid: 12869652
references.citation: Int J Oncol. 2013 Aug;43(2):431-8
references.pmid: 23754252
references.citation: Pharmacogenomics. 2011 Jan;12(1):27-39
references.pmid: 21174620
references.citation: Evid Based Complement Alternat Med. 2013;2013:656351
references.pmid: 23818930
references.citation: Zhong Xi Yi Jie He Xue Bao. 2012 Aug;10(8):901-10
references.pmid: 22883407
references.citation: CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
references.pmid: 21296855
references.citation: Eur J Cancer. 2002 Jul;38(10):1405-12
references.pmid: 12091073
references.citation: Mol Pharmacol. 2010 Jun;77(6):887-94
references.pmid: 20159940
references.citation: Clin Colorectal Cancer. 2011 Jun;10(2):85-96
references.pmid: 21859559
references.citation: Oncol Rep. 2008 Aug;20(2):265-70
references.pmid: 18636185
references.citation: Planta Med. 2006 Oct;72(13):1227-31
references.pmid: 16902872
references.citation: Chin J Integr Med. 2011 Jul;17(7):517-24
references.pmid: 21725877
references.citation: Cancer Res. 2000 Mar 1;60(5):1312-6
references.pmid: 10728692
references.citation: Proc Natl Acad Sci U S A. 1993 Jan 1;90(1):312-6
references.pmid: 7678345
references.citation: Cancer Res. 2012 Sep 15;72(18):4616-21
references.pmid: 22962276
references.citation: J Int Med Res. 2010;38(6):2033-9
references.pmid: 21227007
references.citation: J Zhejiang Univ Sci B. 2006 Dec;7(12):1006-14
references.pmid: 17111471
references.citation: Biochem Cell Biol. 2011 Apr;89(2):138-47
references.pmid: 21455266
references.citation: Evid Based Complement Alternat Med. 2012;2012:908601
references.pmid: 23326293
references.citation: Lung Cancer. 2012 Feb;75(2):228-34
references.pmid: 21788094
references.citation: Evid Based Complement Alternat Med. 2012;2012:276032
references.pmid: 22693529
references.citation: Clin Cancer Res. 2008 Mar 1;14(5):1291-5
references.pmid: 18316546
references.citation: Int J Cancer. 2009 Jun 15;124(12):2905-10
references.pmid: 19296535
references.citation: Anticancer Res. 2013 Apr;33(4):1409-14
references.pmid: 23564780
references.citation: Zhongguo Zhong Xi Yi Jie He Za Zhi. 2010 Jul;30(7):743-7
references.pmid: 20929136
references.citation: Clin Colorectal Cancer. 2013 Mar;12(1):62-9
references.pmid: 23102897
references.citation: Cancer Treat Rev. 2007 Feb;33(1):9-23
references.pmid: 17084534